Ensysce Biosciences, Inc. announced the Investigational Review Board (IRB) approval of PF614-201 protocol, 'A Randomized, Double-Blind, Placebo-Controlled Crossover Study of PF614 on Analgesic Response in the Cold Pressor Test in Healthy male Subjects.' The study will be conducted at Dr. Vince Clinical Research (DVCR) in Overland Park, Kansas, and is designed to confirm time of onset for pain relief by PF614.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.592 USD | +2.96% | +3.86% | -44.15% |
05-28 | Ensysce Biosciences Back in Compliance With Nasdaq | MT |
05-20 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.15% | 4.49M | |
+48.64% | 56.65B | |
-6.44% | 39.44B | |
+38.00% | 39.03B | |
+14.28% | 26.75B | |
-11.17% | 26.86B | |
-21.40% | 19.03B | |
+25.64% | 12.26B | |
+0.96% | 12.28B | |
+27.04% | 12.04B |
- Stock Market
- Equities
- ENSC Stock
- News Ensysce Biosciences, Inc.
- Ensysce Biosciences, Inc. Announces Investigational Review Board Approval of Key Study Protocol